Skip to content

Study · Non-randomized trial · 2011

7 results

Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis.

Daddona PE, Matriano JA, Mandema J, Maa YF

Pharmaceutical research22 Jun 2010Cited by 154 (Europe PMC)

PMID20567999 (opens in a new tab)DOI10.1007/s11095-010-0192-9 (opens in a new tab)PepBankPUB-20567999
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In women with osteoporosis, patch PTH doses showed a proportional increase in plasma PTH AUC.

    In plain wordsIn women with osteoporosis, PTH blood exposure increased proportionally with patch dose.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePlasma PTH AUC dose response
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    20, 30 and 40 µg · transdermal microneedle patchAs given in this study (human).

    Source sentences

    Summary
    In Phase 2, ZP-PTH 20, 30 and 40 µg doses showed a proportional increase in plasma PTH AUC.
    1 context sentence
    Summary · context
    Phase 2 was conducted in post-menopausal women with osteoporosis to determine the patch dose response compared to placebo patch and FORTEO® injection.

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 02HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialPharmacokinetics

    In normal volunteers, patch-delivered PTH had a Tmax three times shorter than FORTEO.

    In plain wordsIn volunteers, patch-delivered PTH reached peak blood levels faster than FORTEO injection.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTime to peak plasma concentration
    Study

    n: not reported in source

    Comparator
    FORTEO injection
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Tmax relative shortening
    3 fold
    versus FORTEO

    Source sentences

    Summary
    Phase 1 ZP-PTH patch delivery demonstrated a rapid PTH plasma pulse profile with T(max) 3 times shorter and apparent T(1/2) 2 times shorter than FORTEO®.
    1 context sentence
    Summary · context
    Phase 1 PK studies evaluated the effect of site of administration, patch wear time and dose in normal volunteers, ages 40-85 yrs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 03HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialPharmacokinetics

    In normal volunteers, patch-delivered PTH had an apparent half-life two times shorter than FORTEO.

    In plain wordsIn volunteers, patch-delivered PTH had a shorter apparent half-life than FORTEO injection.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseApparent half-life
    Study

    n: not reported in source

    Comparator
    FORTEO injection
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Half-life relative shortening
    2 fold
    versus FORTEO

    Source sentences

    Summary
    Phase 1 ZP-PTH patch delivery demonstrated a rapid PTH plasma pulse profile with T(max) 3 times shorter and apparent T(1/2) 2 times shorter than FORTEO®.
    1 context sentence
    Summary · context
    Phase 1 PK studies evaluated the effect of site of administration, patch wear time and dose in normal volunteers, ages 40-85 yrs.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 04HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialPharmacokinetics

    In women with osteoporosis, inter-subject PTH AUC variability was similar across patch doses and comparable to injection.

    In plain wordsIn women with osteoporosis, exposure varied similarly between people across patch doses and injection.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeInter-subject AUC variability
    Study

    n: not reported in source

    Comparator
    Other patch doses and injection
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Inter-subject and intra-subject AUC variability was similar for all patch doses and comparable to injection.
    1 context sentence
    Summary · context
    Phase 2 was conducted in post-menopausal women with osteoporosis to determine the patch dose response compared to placebo patch and FORTEO® injection.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 05HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialPharmacokinetics

    In women with osteoporosis, intra-subject PTH AUC variability was similar across patch doses and comparable to injection.

    In plain wordsIn women with osteoporosis, exposure varied similarly within people across patch doses and injection.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeIntra-subject AUC variability
    Study

    n: not reported in source

    Comparator
    Other patch doses and injection
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Inter-subject and intra-subject AUC variability was similar for all patch doses and comparable to injection.
    1 context sentence
    Summary · context
    Phase 2 was conducted in post-menopausal women with osteoporosis to determine the patch dose response compared to placebo patch and FORTEO® injection.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 06HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In women with osteoporosis, all PTH patch doses significantly increased spine BMD.

    In plain wordsIn women with osteoporosis, all PTH patch doses increased spine bone density significantly.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine BMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    All patch doses produced a significant increase in spine bone mineral density.
    1 context sentence
    Summary · context
    Phase 2 was conducted in post-menopausal women with osteoporosis to determine the patch dose response compared to placebo patch and FORTEO® injection.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 07HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In women with osteoporosis, PTH patches produced an early hip BMD increase that was not observed with injection.

    In plain wordsIn women with osteoporosis, PTH patches increased hip bone density early, unlike injection.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseEarly hip BMD
    Study

    n: not reported in source

    Comparator
    FORTEO injection
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Unexpectedly, ZP-PTH also produced an early increase in hip bone mineral density, an effect not observed with the injection.
    1 context sentence
    Summary · context
    Phase 2 was conducted in post-menopausal women with osteoporosis to determine the patch dose response compared to placebo patch and FORTEO® injection.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.